JP2005529858A - グリセロールエステル誘導体 - Google Patents
グリセロールエステル誘導体 Download PDFInfo
- Publication number
- JP2005529858A JP2005529858A JP2003578313A JP2003578313A JP2005529858A JP 2005529858 A JP2005529858 A JP 2005529858A JP 2003578313 A JP2003578313 A JP 2003578313A JP 2003578313 A JP2003578313 A JP 2003578313A JP 2005529858 A JP2005529858 A JP 2005529858A
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- substituent
- salt
- atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Glycerol ester Chemical class 0.000 title description 45
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 title description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 134
- 125000001424 substituent group Chemical group 0.000 claims abstract description 94
- 239000002502 liposome Substances 0.000 claims abstract description 71
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 55
- 125000003118 aryl group Chemical group 0.000 claims abstract description 46
- 239000002872 contrast media Substances 0.000 claims abstract description 44
- 125000000524 functional group Chemical group 0.000 claims abstract description 43
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 42
- 150000003839 salts Chemical class 0.000 claims abstract description 42
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 37
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 35
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 30
- 239000012528 membrane Substances 0.000 claims abstract description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 20
- 238000003384 imaging method Methods 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 125000005647 linker group Chemical group 0.000 claims description 26
- 239000000470 constituent Substances 0.000 claims description 22
- 125000003277 amino group Chemical group 0.000 claims description 18
- 210000004185 liver Anatomy 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 230000003902 lesion Effects 0.000 claims description 17
- 125000002252 acyl group Chemical group 0.000 claims description 16
- 210000002540 macrophage Anatomy 0.000 claims description 15
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 15
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 14
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims description 12
- 208000019553 vascular disease Diseases 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 210000000952 spleen Anatomy 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 125000002346 iodo group Chemical group I* 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 210000004204 blood vessel Anatomy 0.000 claims description 4
- 210000000981 epithelium Anatomy 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 210000001165 lymph node Anatomy 0.000 claims description 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 210000001365 lymphatic vessel Anatomy 0.000 claims description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract description 19
- 238000002601 radiography Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 description 49
- 238000012360 testing method Methods 0.000 description 35
- 239000000203 mixture Substances 0.000 description 31
- 238000005160 1H NMR spectroscopy Methods 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 238000006467 substitution reaction Methods 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 125000004429 atom Chemical group 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 235000021317 phosphate Nutrition 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 125000000101 thioether group Chemical group 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 125000004442 acylamino group Chemical group 0.000 description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 125000004185 ester group Chemical group 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 125000001033 ether group Chemical group 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- QQHJDPROMQRDLA-UHFFFAOYSA-N hexadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCC(O)=O QQHJDPROMQRDLA-UHFFFAOYSA-N 0.000 description 6
- 239000011630 iodine Substances 0.000 description 6
- 150000002497 iodine compounds Chemical class 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 125000001453 quaternary ammonium group Chemical group 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 125000004434 sulfur atom Chemical group 0.000 description 6
- 239000013078 crystal Substances 0.000 description 5
- 125000006303 iodophenyl group Chemical group 0.000 description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 description 5
- VAPDZNUFNKUROY-UHFFFAOYSA-N 2,4,6-triiodophenol Chemical compound OC1=C(I)C=C(I)C=C1I VAPDZNUFNKUROY-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- QCNWZROVPSVEJA-UHFFFAOYSA-N Heptadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCC(O)=O QCNWZROVPSVEJA-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 125000004423 acyloxy group Chemical group 0.000 description 4
- 125000003368 amide group Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 125000002228 disulfide group Chemical group 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229940074884 iopanoate Drugs 0.000 description 4
- 230000001678 irradiating effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- WQCYAHKAJFZVCO-UHFFFAOYSA-N methyl 15-hydroxypentadecanoate Chemical compound COC(=O)CCCCCCCCCCCCCCO WQCYAHKAJFZVCO-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 4
- HQHCYKULIHKCEB-UHFFFAOYSA-N tetradecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCC(O)=O HQHCYKULIHKCEB-UHFFFAOYSA-N 0.000 description 4
- 231100000820 toxicity test Toxicity 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- RMQQGOCSVRGRJR-UHFFFAOYSA-N 13-(2,4,6-triiodophenoxy)tridecanoic acid Chemical compound OC(=O)CCCCCCCCCCCCOC1=C(I)C=C(I)C=C1I RMQQGOCSVRGRJR-UHFFFAOYSA-N 0.000 description 3
- QNDSITQSTLCYPY-UHFFFAOYSA-N 17-(2,4,6-triiodophenoxy)heptadecanoic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCCOC1=C(I)C=C(I)C=C1I QNDSITQSTLCYPY-UHFFFAOYSA-N 0.000 description 3
- HCUDEUUTSATKFW-UHFFFAOYSA-N 7-(2,4,6-triiodophenoxy)heptanoic acid Chemical compound OC(=O)CCCCCCOC1=C(I)C=C(I)C=C1I HCUDEUUTSATKFW-UHFFFAOYSA-N 0.000 description 3
- XQARKCOGIMGSAQ-UHFFFAOYSA-N 9-(2,4,6-triiodophenoxy)nonanoic acid Chemical compound OC(=O)CCCCCCCCOC1=C(I)C=C(I)C=C1I XQARKCOGIMGSAQ-UHFFFAOYSA-N 0.000 description 3
- BWKDAAFSXYPQOS-UHFFFAOYSA-N Benzaldehyde glyceryl acetal Chemical compound O1CC(O)COC1C1=CC=CC=C1 BWKDAAFSXYPQOS-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010029350 Neurotoxicity Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 206010044221 Toxic encephalopathy Diseases 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 150000004665 fatty acids Chemical group 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000005462 imide group Chemical group 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000193 iodinated contrast media Substances 0.000 description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
- 210000002464 muscle smooth vascular Anatomy 0.000 description 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
- 230000007135 neurotoxicity Effects 0.000 description 3
- 231100000228 neurotoxicity Toxicity 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 235000003441 saturated fatty acids Nutrition 0.000 description 3
- 150000004671 saturated fatty acids Chemical class 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- MFKMOLJNQHPVHC-SNVBAGLBSA-N (2r)-3-[(4-methoxyphenyl)methoxy]propane-1,2-diol Chemical compound COC1=CC=C(COC[C@H](O)CO)C=C1 MFKMOLJNQHPVHC-SNVBAGLBSA-N 0.000 description 2
- BPKYSNQMGKMWGC-ZDUSSCGKSA-N (4s)-4-[(4-methoxyphenyl)methoxymethyl]-2,2-dimethyl-1,3-dioxolane Chemical compound C1=CC(OC)=CC=C1COC[C@@H]1OC(C)(C)OC1 BPKYSNQMGKMWGC-ZDUSSCGKSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- YJCJVMMDTBEITC-UHFFFAOYSA-N 10-hydroxycapric acid Chemical compound OCCCCCCCCCC(O)=O YJCJVMMDTBEITC-UHFFFAOYSA-N 0.000 description 2
- ASUQKWSNPUTSNH-UHFFFAOYSA-N 12-(2,4,6-triiodophenoxy)dodecanoic acid Chemical compound OC(=O)CCCCCCCCCCCOC1=C(I)C=C(I)C=C1I ASUQKWSNPUTSNH-UHFFFAOYSA-N 0.000 description 2
- YYKBWYBUCFHYPR-UHFFFAOYSA-N 12-bromododecanoic acid Chemical compound OC(=O)CCCCCCCCCCCBr YYKBWYBUCFHYPR-UHFFFAOYSA-N 0.000 description 2
- ZDHCZVWCTKTBRY-UHFFFAOYSA-N 12-hydroxylauric acid Chemical compound OCCCCCCCCCCCC(O)=O ZDHCZVWCTKTBRY-UHFFFAOYSA-N 0.000 description 2
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 2
- GPYDWIIQNNHYJO-UHFFFAOYSA-N 13-methoxy-13-oxotridecanoic acid Chemical compound COC(=O)CCCCCCCCCCCC(O)=O GPYDWIIQNNHYJO-UHFFFAOYSA-N 0.000 description 2
- PDLHEABJESSRIC-UHFFFAOYSA-N 15-(2,4,6-triiodophenoxy)pentadecanoic acid Chemical compound OC(=O)CCCCCCCCCCCCCCOC1=C(I)C=C(I)C=C1I PDLHEABJESSRIC-UHFFFAOYSA-N 0.000 description 2
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WFSMVVDJSNMRAR-UHFFFAOYSA-N 2-[2-(2-ethoxyethoxy)ethoxy]ethanol Chemical compound CCOCCOCCOCCO WFSMVVDJSNMRAR-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- UXDDRFCJKNROTO-UHFFFAOYSA-N Glycerol 1,2-diacetate Chemical compound CC(=O)OCC(CO)OC(C)=O UXDDRFCJKNROTO-UHFFFAOYSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- OIRFJRBSRORBCM-UHFFFAOYSA-N Iopanoic acid Chemical compound CCC(C(O)=O)CC1=C(I)C=C(I)C(N)=C1I OIRFJRBSRORBCM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 101100208721 Mus musculus Usp5 gene Proteins 0.000 description 2
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000004378 air conditioning Methods 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 2
- 125000005577 anthracene group Chemical group 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 229960005223 diatrizoic acid Drugs 0.000 description 2
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- INRPVOURYYCLTQ-UHFFFAOYSA-N ethyl 7-(2,4,6-triiodophenoxy)heptanoate Chemical compound CCOC(=O)CCCCCCOC1=C(I)C=C(I)C=C1I INRPVOURYYCLTQ-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- CKDDRHZIAZRDBW-UHFFFAOYSA-N henicosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCC(O)=O CKDDRHZIAZRDBW-UHFFFAOYSA-N 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- GDIMZSDGQZKRLW-UHFFFAOYSA-N methyl 13-hydroxytridecanoate Chemical compound COC(=O)CCCCCCCCCCCCO GDIMZSDGQZKRLW-UHFFFAOYSA-N 0.000 description 2
- RIZOOQYPYGPBOC-UHFFFAOYSA-N methyl 9-hydroxynonanoate Chemical compound COC(=O)CCCCCCCCO RIZOOQYPYGPBOC-UHFFFAOYSA-N 0.000 description 2
- VPAGOPJNXHHESG-UHFFFAOYSA-N methyl 9-methylsulfonyloxynonanoate Chemical compound COC(=O)CCCCCCCCOS(C)(=O)=O VPAGOPJNXHHESG-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 231100001096 no neurotoxicity Toxicity 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- 150000003451 sulfinic acid amides Chemical class 0.000 description 2
- 150000003453 sulfinic acid esters Chemical class 0.000 description 2
- 150000003459 sulfonic acid esters Chemical class 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 231100000216 vascular lesion Toxicity 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- BPKYSNQMGKMWGC-CYBMUJFWSA-N (4r)-4-[(4-methoxyphenyl)methoxymethyl]-2,2-dimethyl-1,3-dioxolane Chemical compound C1=CC(OC)=CC=C1COC[C@H]1OC(C)(C)OC1 BPKYSNQMGKMWGC-CYBMUJFWSA-N 0.000 description 1
- RIWAPWDHHMWTRA-UHFFFAOYSA-N 1,2,3-triiodobenzene Chemical class IC1=CC=CC(I)=C1I RIWAPWDHHMWTRA-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- HNTGIJLWHDPAFN-UHFFFAOYSA-N 1-bromohexadecane Chemical compound CCCCCCCCCCCCCCCCBr HNTGIJLWHDPAFN-UHFFFAOYSA-N 0.000 description 1
- HFGMBJKDPYCVQN-UHFFFAOYSA-N 11-(2,4,6-triiodophenoxy)undecanoic acid Chemical compound OC(=O)CCCCCCCCCCOC1=C(I)C=C(I)C=C1I HFGMBJKDPYCVQN-UHFFFAOYSA-N 0.000 description 1
- QFGCFKJIPBRJGM-UHFFFAOYSA-N 12-[(2-methylpropan-2-yl)oxy]-12-oxododecanoic acid Chemical compound CC(C)(C)OC(=O)CCCCCCCCCCC(O)=O QFGCFKJIPBRJGM-UHFFFAOYSA-N 0.000 description 1
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 1
- LNMKWGZJGCLKMY-UHFFFAOYSA-N 14-(2,4,6-triiodophenoxy)tetradecanoic acid Chemical compound OC(=O)CCCCCCCCCCCCCOC1=C(I)C=C(I)C=C1I LNMKWGZJGCLKMY-UHFFFAOYSA-N 0.000 description 1
- ULZDDSFUVVWTBD-UHFFFAOYSA-N 16-(2,4,6-triiodophenoxy)hexadecanoic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCOC1=C(I)C=C(I)C=C1I ULZDDSFUVVWTBD-UHFFFAOYSA-N 0.000 description 1
- PFNCOYVEMJYEED-UHFFFAOYSA-N 16-bromohexadecanoic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCBr PFNCOYVEMJYEED-UHFFFAOYSA-N 0.000 description 1
- ZMZGFLUUZLELNE-UHFFFAOYSA-N 2,3,5-triiodobenzoic acid Chemical compound OC(=O)C1=CC(I)=CC(I)=C1I ZMZGFLUUZLELNE-UHFFFAOYSA-N 0.000 description 1
- YMQRPXBBBOXHNZ-UHFFFAOYSA-N 2-chloro-1-morpholin-4-ylethanone Chemical compound ClCC(=O)N1CCOCC1 YMQRPXBBBOXHNZ-UHFFFAOYSA-N 0.000 description 1
- XBPPLECAZBTMMK-UHFFFAOYSA-N 2-chloro-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CCl XBPPLECAZBTMMK-UHFFFAOYSA-N 0.000 description 1
- UBDUXVILYVIFKH-UHFFFAOYSA-N 2-morpholin-4-ylbutanedioic acid Chemical compound OC(=O)CC(C(O)=O)N1CCOCC1 UBDUXVILYVIFKH-UHFFFAOYSA-N 0.000 description 1
- QMQFFHSJUJDRPG-UHFFFAOYSA-N 3-amino-2,4,6-triiodobenzoic acid Chemical compound NC1=C(I)C=C(I)C(C(O)=O)=C1I QMQFFHSJUJDRPG-UHFFFAOYSA-N 0.000 description 1
- YUYHRSGXZZVNMS-UHFFFAOYSA-N 3-morpholin-4-ylpropanoic acid Chemical compound OC(=O)CCN1CCOCC1 YUYHRSGXZZVNMS-UHFFFAOYSA-N 0.000 description 1
- YYSCJLLOWOUSHH-UHFFFAOYSA-N 4,4'-disulfanyldibutanoic acid Chemical compound OC(=O)CCCSSCCCC(O)=O YYSCJLLOWOUSHH-UHFFFAOYSA-N 0.000 description 1
- DWHLWJHNQZWFBA-UHFFFAOYSA-N 4-hexylmorpholine Chemical compound CCCCCCN1CCOCC1 DWHLWJHNQZWFBA-UHFFFAOYSA-N 0.000 description 1
- PNHMBKXVXNJADT-UHFFFAOYSA-N 4-morpholin-4-ium-4-ylbutanoate Chemical compound OC(=O)CCCN1CCOCC1 PNHMBKXVXNJADT-UHFFFAOYSA-N 0.000 description 1
- BSVYXFWQDRWOFH-UHFFFAOYSA-N 5-morpholin-4-ylpentanoic acid Chemical compound OC(=O)CCCCN1CCOCC1 BSVYXFWQDRWOFH-UHFFFAOYSA-N 0.000 description 1
- GNOGSFBXBWBTIG-UHFFFAOYSA-N Acetrizoic acid Chemical compound CC(=O)NC1=C(I)C=C(I)C(C(O)=O)=C1I GNOGSFBXBWBTIG-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 238000006218 Arndt-Eistert homologation reaction Methods 0.000 description 1
- 238000006754 Barbier-Wieland degradation reaction Methods 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- JJOJFIHJIRWASH-UHFFFAOYSA-N Eicosanedioic acid Natural products OC(=O)CCCCCCCCCCCCCCCCCCC(O)=O JJOJFIHJIRWASH-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- ZWVXWBDLRNACOZ-UHFFFAOYSA-N IC1=C(OC(C(=O)O)CCCCCCCCCCCCCCC)C(=CC(=C1)I)I Chemical compound IC1=C(OC(C(=O)O)CCCCCCCCCCCCCCC)C(=CC(=C1)I)I ZWVXWBDLRNACOZ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- VIWZVFVJPXTXPA-UHFFFAOYSA-N N-(2-Carboxymethyl)-morpholine Chemical compound OC(=O)CN1CCOCC1 VIWZVFVJPXTXPA-UHFFFAOYSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- RNVYQYLELCKWAN-YFKPBYRVSA-N [(4s)-2,2-dimethyl-1,3-dioxolan-4-yl]methanol Chemical compound CC1(C)OC[C@H](CO)O1 RNVYQYLELCKWAN-YFKPBYRVSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- OZOBNBRCHCPBJL-UHHODNAUSA-N [[(3r,10r,13r,17r)-3-hydroxy-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-1,2,4,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-yl]amino] 2-[(2,4,6-triiodophenyl)methyl]butanoate Chemical compound N([C@]1(O)CC2=CCC3C4CC[C@@H]([C@@]4(C)CCC3[C@@]2(C)CC1)[C@H](C)CCCC(C)C)OC(=O)C(CC)CC1=C(I)C=C(I)C=C1I OZOBNBRCHCPBJL-UHHODNAUSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 229960005216 acetrizoic acid Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical class O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005162 aryl oxy carbonyl amino group Chemical group 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- VWWMOACCGFHMEV-UHFFFAOYSA-N dicarbide(2-) Chemical compound [C-]#[C-] VWWMOACCGFHMEV-UHFFFAOYSA-N 0.000 description 1
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
- 229940093541 dicetylphosphate Drugs 0.000 description 1
- JTXUVYOABGUBMX-UHFFFAOYSA-N didodecyl hydrogen phosphate Chemical compound CCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCC JTXUVYOABGUBMX-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 108700003601 dimethylglycine Proteins 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- CYFHLEMYBPQRGN-UHFFFAOYSA-N ditetradecyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCC CYFHLEMYBPQRGN-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- OOBFNDGMAGSNKA-UHFFFAOYSA-N ethyl 7-bromoheptanoate Chemical compound CCOC(=O)CCCCCCBr OOBFNDGMAGSNKA-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
- 229960002979 iopanoic acid Drugs 0.000 description 1
- GOIQOQCNFWYSTQ-UHFFFAOYSA-N iophenoic acid Chemical compound CCC(C(O)=O)CC1=C(I)C=C(I)C(O)=C1I GOIQOQCNFWYSTQ-UHFFFAOYSA-N 0.000 description 1
- 229950004657 iophenoic acid Drugs 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- HFNPVFKUZYCDIB-UHFFFAOYSA-N methyl 11-bromoundecanoate Chemical compound COC(=O)CCCCCCCCCCBr HFNPVFKUZYCDIB-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 229940078490 n,n-dimethylglycine Drugs 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940089513 pentadecalactone Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- DXNCZXXFRKPEPY-UHFFFAOYSA-N tridecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCC(O)=O DXNCZXXFRKPEPY-UHFFFAOYSA-N 0.000 description 1
- 210000004231 tunica media Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0461—Dispersions, colloids, emulsions or suspensions
- A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
- A61K51/1234—Liposomes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/05—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/14—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/708—Ethers
- C07C69/712—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Fats And Perfumes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
下記の一般式(IA):
【化1】
(式中、Ar1は水素原子を示すか、又は少なくとも1個のヨウ素原子を置換基として有するアリール基を示し;Ar2は少なくとも1個のヨウ素原子を置換基として有するアリール基を示し;L1及びL2はそれぞれ独立に主鎖が6個以上の炭素原子を含む2価の連結基を示し;L3は単結合を示すか、又は主鎖が1〜6個の炭素原子と1個の酸素原子とを含む2価の連結基を示し;Xは少なくとも1個のヘテロ原子を含む官能基を示すが、L3が単結合である場合にはXは水酸基以外の官能基を示す)で表される化合物又はその塩。該化合物はリポソームの膜構成成分として利用することができ、該リポソームはX線造影剤として用いることができる。
Description
また、本発明は、グリセロリン酸エステル誘導体に関する。より詳しくは、ヨードフェニル基を有する1,3−ジアシル−2−フォスフォグリセリド化合物、および2,3−ジアシル−1−フォスフォグリセリド化合物に関する。
これらの化合物はリポソームの膜構成成分として利用することができ、該リポソームはX線造影剤として用いることができる。
すなわち、本発明は、下記の一般式(IA):
で表される化合物又はその塩を提供するものである。
−N(R1)(R2)
(式中、R1及びR2はそれぞれ独立に水素原子を示すか、あるいは置換基を有していてもよい炭素数1〜10のアルキル基又は置換基を有していてもよい炭素数1〜10のアシル基を示し、R1とR2とは互いに結合して環を形成してもよい)で表される基、又は
下記の一般式(IIIA):
−O−R3
(式中、R3は水素原子を示すか、あるいは置換基を有していてもよい炭素数1〜10のアルキル基又は置換基を有していてもよい炭素数1〜10のアシル基を示す)で表される基である上記の化合物又はその塩;及びR3が水素原子であるか、又はアルコキシ基、水酸基、及びアミノ基からなる群から選ばれる置換基を少なくとも1つ有する炭素数1〜10のアルキル基である上記の化合物又はその塩が提供される。
また、本発明により、下記の一般式(IB):
下記の一般式(IIB):
−(CH2)n−O−、−(CH2)m−S−CH2−、−(CH2)m−(C=O)O−、
−(CH2)m−(C=O)NH−、−(CH2)m−O(C=O)−、−(CH2)m−NH(C=O)−、
−(CH2)p−NH(C=O)−(CH2)2−O−、−CH2−CH=CH−(CH2)q−O−、
−(CH2)m−CH(CH3)−O−
(式中、nは6から30の任意の整数を示し;mは5から29の任意の整数を示し; pは4から28の任意の整数を示し;qは3から27の任意の整数を示す)
−(CH2)n−(C=O)O−、−(C=O)−(CH2)nO−、−(CH2)mO−、
−(C=O) (CH2)p−(C=O)O−、単結合
(式中、nは0から5の任意の整数を示し;mは1から6の任意の整数を示し;pは1から4の任意の整数を表す)
−(CH2)n−O−、−(CH2)m−S−CH2−、−(CH2)m−(C=O)O−、
−(CH2)m−(C=O)NH−、−(CH2)m−O(C=O)−、−(CH2)m−NH(C=O)−、
−(CH2)p−NH(C=O)−(CH2)2−O−、−CH2−CH=CH−(CH2)q−O−、
−(CH2)m−CH(CH3)−O−
(式中、nは6から30の任意の整数を示し;mは5から29の任意の整数を示し; pは4から28の任意の整数を示し;qは3から27の任意の整数を示す)
ヘプタデカン二酸より、ヘキサデカン二酸モノ2,4,6-トリヨードフェニルと同様の手法でヘプタデカン二酸モノ2,4,6-トリヨードフェニルを得た。
16-ブロモヘキサデカン酸より、12-(2,4,6-トリヨードフェノキシ)ドデカン酸の合成法と同様に16-(2,4,6-トリヨードフェノキシ)ヘキサデカン酸を合成した。
9-ヒドロキシノナン酸メチル2.1gとピリジン1.8gをジクロロメタン20mLに加え、0℃で攪拌し、メタンスルホニルクロリド1.3mLを加えて、徐々に室温まで昇温し、1日攪拌した。水を加えた後、ジクロロメタンで2回抽出し、得られた有機層を1規定塩酸、飽和炭酸水素ナトリウム溶液で洗浄した。有機層を無水硫酸ナトリウムで乾燥後、除媒し、得られた残渣をシリカゲルカラムクロマトグラフィーで精製して9-(メタンスルホニルオキシ)ノナン酸メチルを2.1g(収率68%)得た。
15-ペンタデカラクトン25.6gをメタノール150mLに加え、さらに28%ナトリウムメトキシド溶液を50mL加えて3時間還流した。1規定塩酸を加えて酢酸エチルで3回抽出し、有機相を飽和食塩水で洗浄した後、無水硫酸マグネシウムで乾燥し、除媒した。15-ヒドロキシペンタデカン酸メチルを28.5g(収率98%)得た。
15-ヒドロキシペンタデカン酸メチルを用いて、9-(2,4,6-トリヨードフェノキシ)ノナン酸と同様の手法で15-(2,4,6-トリヨードフェノキシ)ペンタデカン酸を得た。
13-ヒドロキシトリデカン酸メチルを用いて、9-(2,4,6-トリヨードフェノキシ)ノナン酸と同様の手法で13-(2,4,6-トリヨードフェノキシ)トリデカン酸を得た。
エイコサン二酸を用いて、13-(2,4,6-トリヨードフェノキシ)トリデカン酸と同様の手法で20-(2,4,6-トリヨードフェノキシ)エイコサン酸を得た。
17-(2,4,6-トリヨードフェノキシ)ヘプタデカン酸を用いて、17-(2,4,6-トリヨードフェノキシ)ヘプタデカン酸と同様の手法で、19-(2,4,6-トリヨードフェノキシ)ナノデカン酸を得た。
合成したトリヨードフェノキシアルキルカルボン酸を用いて、J. Med. Chem., 29(12), 2457 (1986)に記載の方法に準拠して1,3−ジアシルグリセロール体を得た。
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 5.35-5.28 (1H, m) 4.33 (2H, dd) 4.16 (2H, dd) 3.93 (4H, t) 3.79-3.72 (4H, m) 3.23 (2H, s) 2.63-2.56 (4H,m) 2.31 (4H, t) 1.89 (4H, quin) 1.70-1.48 (8H, m) 1.43-1.20 (20H, m)
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 5.32-5.24 (1H, m) 4.30 (2H, dd) 4.18 (2H, dd) 3.92 (4H, t) 3.72-3.65 (4H, m) 2.69 (2H, t) 2.52 (2H, t) 2.48-2.42 (4H,m) 2.32 (4H, t) 1.89 (4H, quin) 1.70-1.48 (8H, m) 1.43-1.20 (20H, m)
1A−3−2:
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 5.28-5.22 (1H, m) 4.31 (2H, dd) 4.15 (2H, dd) 3.92 (4H, t) 3.72-3.67 (4H, m) 2.46-2.39 (4H, m) 2.39 (2H, t) 2.35 (2H, t) 2.32 (4H, t) 1.89 (4H, quin) 1.81 (4H, quin) 1.70-1.48 (8H, m) 1.43-1.20 (20H, m)
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 5.30-5.22 (1H, m) 4.30 (2H, dd) 4.15 (2H, dd) 3.92 (4H, t) 3.75-3.67 (4H, m) 2.45-2.28 (12H, m) 1.89 (4H, quin) 1.72-1.48 (12H, m) 1.43-1.20 (20H, m)
1A−3−4:
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 5.32-5.22 (1H, m) 4.30 (2H, dd) 4.15 (2H, dd) 3.94 (4H, t) 3.77-3.67 (4H, m) 2.49-2.28 (12H, m) 1.89 (4H, quin) 1.72-1.48 (14H, m) 1.43-1.20 (20H, m)
1A−4−1:
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 5.30-5.22 (1H, m) 4.31 (2H, dd) 4.17 (2H, dd) 3.93 (4H, t) 3.72-356 (6H, m) 3.49 (2H, t) 2.73-2.58 (4H, m) 2.32 (4H, t) 1.89 (4H, quin) 1.70-1.48 (8H, m) 1.43-1.20 (20H, m)
1A−4−4:
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 5.32-5.24 (1H, m) 4.31 (2H, dd) 4.17 (2H, dd) 3.93 (4H, t) 2.72-2.61 (4H, m) 2.32 (4H, t) 1.89 (4H, quin) 1.70-1.48 (8H, m) 1.43-1.20 (20H, m)
1A−4−2:
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 5.61 (1H, brs) 5.35-5.20 (2H, m) 4.32 (2H, dd) 4.18 (2H, dd) 3.93 (4H, t) 2.70 (2H, t) 2.53 (2H, t) 2.32 (4H, t) 1.89 (4H, quin) 1.70-1.48 (8H, m) 1.43-1.20 (20H, m)
1A−4−3:
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 5.35-5.22 (1H, m) 4.32 (2H, dd) 4.18 (2H, dd) 3.93 (4H, t) 3.05 (3H, s) 2.95 (3H, s) 2.75-2.59 (4H, m) 2.32 (4H, t) 1.89 (4H, quin) 1.70-1.48 (8H, m) 1.43-1.20 (20H, m)
1A−4−5:
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 5.32-5.24 (1H, m) 4.31 (2H, dd) 4.40-4.34 (2H, m) 4.17 (2H, dd) 3.93 (4H, t) 3.76-3.60 (10H, m) 3.56 (2H, q) 2.70-2.60 (4H, brs) 2.32 (4H, t) 1.89 (4H, quin) 1.70-1.48 (8H, m) 1.43-1.20 (23H, m)
1A−5−1:
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 4.29 (2H, s) 4.28 (2H, dd) 4.15 (2H, dd) 3.92 (4H, t) 3.90-3.82 (1H, m) 3.72-3.63 (4H, m) 3.64-3.58 (2H, m) 3.53-3.47 (2H, m) 2.33 (4H, t) 1.89 (4H, quin) 1.70-1.48 (8H, m) 1.43-1.20 (20H, m)
1A−5−3:
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 4.29 (2H, s) 4.28 (2H, dd) 4.18 (2H, dd) 3.92 (4H, t) 3.90-3.82 (1H, m) 3.00 (3H, s) 2.96 (3H, s) 2.33 (4H, t) 1.89 (4H, quin) 1.70-1.48 (8H, m) 1.43-1.20 (20H, m)
1A−5−4:
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 4.32 (2H, dd) 4.27 (2H, s) 4.13 (2H, dd) 3.92 (4H, t) 3.90-3.82 (1H, m) 2.37 (4H, t) 1.90 (4H, quin) 1.70-1.48 (8H, m) 1.43-1.20 (20H, m)
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 6.76 (1H, bs) 5.46 (1H, bs) 4.29 (2H, dd) 4.14 (2H, dd) 4.12 (2H, s) 3.92 (4H, t) 3.85-3.76 (1H, m) 2.34 (4H, t) 1.89 (4H, quin) 1.70-1.48 (8H, m) 1.43-1.20 (20H, m)
1A−5−10:
1H-NMR (300MHz, CDCl3) δ : 9.35 (1H, bs) 8.05 (4H, s) 4.68 (2H, s) 4.28 (2H, dd) 4.22 (2H, dd) 3.93 (4H, t) 3.90-3.80 (1H, m) 3.67 (2H, t) 3.25 (2H, dq) 2.34 (4H, t) 2.29 (2H, t) 2.22 (6H, s) 1.89 (4H, quin) 1.82 (2H, quin) 1.70-1.48 (8H, m) 1.43-1.20 (20H, m)
1A−5−11:
1H-NMR (300MHz, CDCl3) δ : 9.00 (1H, bs) 8.05 (4H, s) 4.51 (2H, s) 4.31 (2H, dd) 4.22 (2H, dd) 3.93 (4H, t) 3.93-3.83 (1H, m) 3.68 (2H, q) 3.36 (2H, q) 2.41 (2H, t) 2.34 (4H, t) 2.28 (6H, s) 1.89 (4H, quin) 1.77 (2H, quin) 1.70-1.48 (8H, m) 1.43-1.20 (20H, m)
1A−6−3:
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 5.40-5.30 (1H, m) 4.33 (2H, dd) 4.16 (2H, dd) 3.93 (4H, t) 3.22 (2H, s) 2.38 (6H, s) 2.33 (4H, t) 1.89 (4H, quin) 1.70-1.48 (8H, m) 1.43-1.20 (20H, m)
上記カルボン酸を用い、化合物1A−1−3と同様の手法により化合物1A−6−8のアセトニド保護体を得た。さらに、化合物1A−5−4と同様の手法で脱保護反応を行い、化合物1A−6−8を得た。
1A−6−8:
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 5.40-5.30 (1H, m) 4.36 (2H, dd) 4.17 (2H, dd) 4.16 (2H, s) 3.93 (4H, t) 3.95-3.85 (1H, m) 3.75-3.50 (4H, m) 2.33 (4H, t) 1.89 (4H, quin) 1.70-1.48 (8H, m) 1.43-1.20 (20H, m)
1A−6−9:
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 5.38-5.29 (1H, m) 4.38 (2H, dd) 4.30 (2H, s) 4.16 (2H, dd) 3.93 (4H, t) 3.75-3.65 (4H, m) 3.57 (1H, quin) 2.68 (2H, bs) 2.33 (4H, t) 1.89 (4H, quin) 1.70-1.48 (8H, m) 1.43-1.20 (20H, m)
上記のトシル体を用い、化合物1A−5−1と同様の手法で化合物1A−7−3を得た。
1A−7−3:
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 4.20 (2H, dd) 4.14 (2H, dd) 3.93 (4H, t) 3.82-3.72 (3H, m) 3.68-3.56 (10H, m) 3.53 (2H, q) 2.32 (4H, t) 1.89 (4H, quin) 1.70-1.48 (8H, m) 1.43-1.20 (23H, m)
1A−7−5:
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 4.28 (2H, dd) 4.18 (2H, dd) 3.93 (4H, t) 3.84-3.75 (1H, m) 3.72 (4H, bs) 2.37 (4H, t) 1.90 (4H, quin) 1.70-1.48 (8H, m) 1.43-1.20 (20H, m)
1A−7−6:
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 4.29 (2H, ddd) 4.10 (2H, dd) 3.93 (4H, t) 3.88-3.58 (6H, m) 2.33 (4H, t) 1.89 (4H, quin) 1.70-1.48 (8H, m) 1.43-1.20 (20H, m)
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 4.59-4.48 (1H, m) 4.35 (2H, brs) 4.30-4.20 (4H, m) 3.92 (4H, t) 3.83 (2H, brs) 3.39 (9H, s) 2.30 (4H, t) 1.99 (4H, quin) 1.68-1.43 (8H, m) 1.43-1.20 (20H, m)
1B−1−4:
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 4.59-4.48 (1H, m) 4.35 (2H, brs) 4.30-4.20 (4H, m) 3.92 (4H, t) 3.83 (2H, brs) 3.39 (9H, s) 2.30 (4H, t) 1.99 (4H, quin) 1.68-1.43 (8H, m) 1.43-1.20 (24H, m)
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 4.59-4.48 (1H, m) 4.35 (2H, brs) 4.30-4.20 (4H, m) 3.92 (4H, t) 3.83 (2H, brs) 3.39 (9H, s) 2.30 (4H, t) 1.99 (4H, quin) 1.68-1.43 (8H, m) 1.43-1.20 (36H, m)
1B−1−8:
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 4.59-4.48 (1H, m) 4.35 (2H, brs) 4.30-4.20 (4H, m) 3.92 (4H, t) 3.83 (2H, brs) 3.39 (9H, s) 2.30 (4H, t) 1.99 (4H, quin) 1.68-1.43 (8H, m) 1.43-1.20 (40H, m)
1H-NMR (300MHz, CDCl3) δ : 8.04 (4H, s) 5.26-5.18 (1H, m) 4.40 (1H, dd) 4.40-4.30 (2H, brs) 4.13 (1H, dd) 4.02-3.90 (2H, m) 3.92 (4H, t) 3.82 (2H, brs) 3.39 (9H, s) 2.30 (4H, m) 1.89 (4H, quin) 1.68-1.43 (8H, m) 1.43-1.20 (20H, m)
1B−9−1:
1H-NMR (300MHz, CDCl3) δ : 8.04 (4H, s) 4.50 (1H, drs) 4.25 (4H, brs) 3.92 (4H, t) 2.38-1.27 (4H, m) 1.88 (4H, quin) 1.62-1.45 (8H, m) 1.45-1.20 (20H, m)
1H-NMR (300MHz, CDCl3) δ : 8.05 (4H, s) 4.75-4.65 (1H, m) 4.33 (2H, dd) 4.23 (2H, dd) 4.20-4.10 (2H, m) 3.92 (4H, t) 3.85-3.54 (3H, m) 2.36 (4H, t) 1.99 (4H, quin) 1.68-1.48(8H, m) 1.43-1.20 (20H, m)
1B−9−3:
1H-NMR (300MHz, CDCl3&CD3 OD) δ : 8.05 (4H, s) 4.58-4.46 (1H, m) 4.38-4.28 (2H, brs) 4.28-4.19 (4H, m) 4.10-4.03 (1H, m) 3.92 (4H, t) 2.33 (4H, dt) 1.89 (4H, quin) 1.68-1.43 (8H, m) 1.43-1.20 (40H, m)
下記に示した割合でジ・パルミトイル PC(フナコシ社製、No.1201-41-0225)、ジ・パルミトイル PS(フナコシ社製、No.1201-42-0237)をJ. Med. Chem., 25(12), 1500 (1982)記載の方法で、本発明のヨード化合物とナス型フラスコ内でクロロホルムに溶解して均一溶液とした後、溶媒を減圧で留去してフラスコ底面に薄膜を形成した。この薄膜を真空で乾燥後、0.9%生理食塩水(光製薬社製、No.512)を適当量加え、超音波照射(Branson社製、No.3542プローブ型発振器、0.1mW)を氷冷下5分実施することにより、均一なリポソーム分散液を得た。得られた分散液の粒径をWBCアナライザー(日本光電社製、A-1042)で測定した結果、粒子径は40から65nmであった。この方法により調製した下記リポソーム製剤を国際公開 WO 01/82977に記載の血管平滑筋細胞とマクロファージとの混合培養系に添加し、37℃、5%CO2で24時間培養した後、血管平滑筋細胞に取り込まれたヨード化合物を定量した。このように本発明の化合物は効率よく血管平滑筋細胞に取り込ませることができ、X線造影剤のためのリポソームの構成脂質として優れた性質を有することが明らかである。
Invest. radiol. 18, 275 (1985)の方法に従い、ラット大動脈に動脈硬化巣を形成させた。動脈硬化巣を形成したラットに前出で調製した1A−4−1のリポソーム製剤200mg/kgを頚静脈より慎重に投与した。投与10分後、X線撮影により明瞭な動脈硬化巣の造影写真が得られた。その結果を図1〜3に示す。
ICRマウス雄6週齢(日本チャールスリバー)を購入し、1週間の検疫期間の後、クリーン動物舎内(空調:へパフィルター クラス1000、室温:20℃〜24℃ 湿度:35%〜60%)で1週間馴化した。その後、MTD値を求めるため、尾静脈よりリポソーム製剤を投与した。リポソーム製剤は、生理食塩水(光製薬社製)又はグルコース溶液(大塚製薬社製)のいずれかを溶媒として投与した。次に求められたMTD値をもとに、その1/2量を3日間、尾静脈より3日間連続で投与した(n=3匹とする)。症状観察は各投与後6時間までとし、投与終了後剖検を行ない、主要臓器について所見を取ったところ、異常は認められなかった。
Wistarラット雄 6週齢(日本チャールスリバー)を購入し、1週間の検疫期間の後、クリーン動物舎内(空調:へパフィルター クラス1000、室温:20℃〜24℃ 湿度:35%〜60%)で1週間馴化した。ペントバルビタール(万有製薬社製)を1mg/kg腹腔内に投与し、10〜15分程度静置した後、マウス3日間連続投与毒性試験で求めたマウスのMTD値の1/2量のリポソーム製剤を尾静脈より投与した。リポソーム製剤は、生理食塩水(光製薬社製)又はグルコース溶液(大塚製薬社製)のいずれかを溶媒として投与した。投与後、少なくとも4時間まで、自発運動、顔面・四肢の痙攣の有無を観察した。本発明の化合物のいずれについても神経毒性は認められなかった。
SDラット雄6週齢(日本チャールスリバー社製)を購入し1週間馴化した。1週間馴化後、体重を測定し、断頭放血した。肝臓を摘出し、冷却した0.15M KClで3回洗浄した。洗浄後、肝臓の湿重量を測定し、その重量の3倍の冷却した0.15M KClを加え、ホモジナイザーに移した。氷冷中でホモジネイトし、その後、ホモジネイトを9000gで10分間冷却遠心した。この上清をS9と呼び、−80℃以下で保存した。
試験例1と同様の方法により、下記に示した割合でジ・パルミトイル PC(フナコシ社製、No.1201-41-0225)、ジ・パルミトイル PS(フナコシ社製、No.1201-42-0237)を含むリポソーム製剤を調製した。粒子径は40から65nmであった。この方法により調製した下記リポソーム製剤を国際公開 WO 01/82977に記載の血管平滑筋細胞とマクロファージとの混合培養系に添加し、37℃、5%CO2で24時間培養した後、血管平滑筋細胞に取り込まれたヨード化合物を定量した。このように本発明の化合物は効率よく血管平滑筋細胞に取り込ませることができ、X線造影剤のためのリポソームの構成脂質として優れた性質を有することが明らかである。
試験例2と同様にして、動脈硬化巣を形成したラットに前出で調製した1B−1−3のリポソーム製剤200mg/kgを頚静脈より慎重に投与した。投与1分後、X線撮影により明瞭な動脈硬化巣の造影写真が得られた。その結果を図4〜7に示す。
試験例3と同様にして、マウスを用いて3日間連続投与による毒性試験を行った。その結果、主要臓器についての所見に異常は認められなかった。
試験例4と同様にしてWistarラット神経毒性試験を行った。この結果、本発明の化合物1B−1−3及び2B−1−3のいずれについても神経毒性は認められなかった。
試験例5と同様にしてS9Mixを調製し、試験例5と同様にしてS9Mix中の被験物質量(未変化体)を経時でHPLCを用い測定した。本発明の化合物はS9分解試験において効率的に分解されることが明らかであり、X線造影剤のためのリポソームの構成脂質として優れた性質を有することが明らかである。
ICRマウス雄6週齢(日本チャールスリバー社製)を購入し1週間馴化した。1週間馴化後体重を測定し、尾静脈より被験物質を200mg/kgになる様に投与した(テルモシリンジ、針24G:テルモ社製)。被験物質はDMSO(和光純薬社製)で溶解した後、マウス血清で稀釈し、マウス1匹あたりの投与量(体積)が200μlを超えない様にした。投与後マウスを頚椎脱臼にて処理し、すばやく肝臓をとりだし、ホモジネイト後HPLCにて肝臓中の被験物質を定量した。結果を図8に示す。
Claims (28)
- 下記の一般式(IA):
で表される化合物又はその塩。 - Ar2が少なくとも3個のヨウ素原子を置換基として有するフェニル基である請求項1に記載の化合物又はその塩。
- Ar1が少なくとも1個のヨウ素原子を置換基として有するアリール基である請求項1又は2に記載の化合物又はその塩。
- Ar1及びAr2がそれぞれ独立に少なくとも3個のヨウ素原子を置換基として有するフェニル基である請求項1に記載の化合物又はその塩。
- Xが下記の一般式(IIA):
−N(R1)(R2)
(式中、R1及びR2はそれぞれ独立に水素原子を示すか、あるいは置換基を有していてもよい炭素数1〜10のアルキル基又は置換基を有していてもよい炭素数1〜10のアシル基を示し、R1とR2とは互いに結合して環を形成してもよい)で表される基、又は
下記の一般式(IIIA):
−O−R3
(式中、R3は水素原子を示すか、あるいは置換基を有していてもよい炭素数1〜10のアルキル基又は置換基を有していてもよい炭素数1〜10のアシル基を示す)で表される基である請求項1ないし4のいずれか1項に記載の化合物又はその塩。 - R3が水素原子であるか、又はアルコキシ基、水酸基、及びアミノ基からなる群から選ばれる置換基を少なくとも1つ有する炭素数1〜10のアルキル基である請求項5に記載の化合物又はその塩。
- 下記の一般式(IB):
- Ar11が少なくとも3個のヨウ素原子を置換基として有するフェニル基である請求項7に記載の化合物又はその塩。
- Ar11及びAr12がそれぞれ独立に少なくとも1個のヨウ素原子を置換基として有するアリール基である請求項7に記載の化合物又はその塩。
- Ar11及びAr12がそれぞれ独立に少なくとも3個のヨウ素原子を置換基として有するフェニル基である請求項7に記載の化合物又はその塩。
- 下記の一般式(IIB):
- Ar13又はAr14のいずれか一方が少なくとも3個のヨウ素原子を置換基として有するフェニル基である請求項11に記載の化合物又はその塩。
- Ar13及びAr14がそれぞれ独立に少なくとも1個のヨウ素原子を置換基として有するアリール基である請求項11に記載の化合物又はその塩。
- Ar13及びAr14がそれぞれ独立に少なくとも3個のヨウ素原子を置換基として有するフェニル基である請求項11に記載の化合物又はその塩。
- 請求項1ないし14のいずれか1項に記載の化合物又はその塩を膜構成成分として含むリポソーム。
- ホスファチジルコリン及びホスファチジルセリンを膜構成成分として含む請求項15に記載のリポソーム。
- 請求項15又は16に記載のリポソームを含むX線造影剤。
- 血管疾患の造影に用いる請求項17に記載のX線造影剤。
- 泡沫化マクロファージの影響で異常増殖した血管平滑筋細胞の造影に用いる請求項17に記載のX線造影剤。
- マクロファージが局在化する組織又は疾患部位の造影に用いる請求項17に記載のX線造影剤。
- マクロファージが局在化する組織が肝臓、脾臓、肺胞、リンパ節、リンパ管、及び腎臓上皮からなる群から選ばれる請求項20に記載のX線造影剤。
- マクロファージが局在化する疾患部位が腫瘍、炎症部位、及び感染部位からなる群から選ばれる請求項20に記載のX線造影剤。
- 少なくとも1つのヨード原子が放射性同位体である請求項1ないし14のいずれか1項に記載の化合物又はその塩を膜構成成分として含むリポソーム。
- 請求項23に記載のリポソームを含むシンチグラフィー造影剤。
- 泡沫化マクロファージの影響で異常増殖した血管平滑筋細胞の造影に用いる請求項24に記載のシンチグラフィー造影剤。
- マクロファージが局在化する組織又は疾患部位の造影に用いる請求項24に記載のシンチグラフィー造影剤。
- 造影対象の組織が血管、肝臓、脾臓、肺胞、リンパ節、リンパ管、及び腎臓上皮からなる群から選ばれる請求項24に記載のシンチグラフィー造影剤。
- 腫瘍、動脈硬化巣、炎症部位、及び感染部位からなる群から選ばれる疾患部位の造影に用いる請求項24に記載のシンチグラフィー造影剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002088694 | 2002-03-27 | ||
JP2002088695 | 2002-03-27 | ||
PCT/JP2003/003814 WO2003080554A2 (en) | 2002-03-27 | 2003-03-27 | Iodinated triglyceride analogs |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005529858A true JP2005529858A (ja) | 2005-10-06 |
JP4464687B2 JP4464687B2 (ja) | 2010-05-19 |
Family
ID=28456284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003578313A Expired - Fee Related JP4464687B2 (ja) | 2002-03-27 | 2003-03-27 | グリセロールエステル誘導体 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7371877B2 (ja) |
EP (1) | EP1492776B1 (ja) |
JP (1) | JP4464687B2 (ja) |
AT (1) | ATE412641T1 (ja) |
AU (1) | AU2003219554A1 (ja) |
DE (1) | DE60324401D1 (ja) |
WO (1) | WO2003080554A2 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103980154B (zh) | 2007-07-12 | 2015-02-25 | 通用电气医疗集团股份有限公司 | 造影剂 |
CN101820923A (zh) | 2007-10-12 | 2010-09-01 | 通用电气医疗集团股份有限公司 | 对比剂 |
CN101820922A (zh) | 2007-10-12 | 2010-09-01 | 通用电气医疗集团股份有限公司 | 对比剂 |
CN101821231A (zh) | 2007-10-12 | 2010-09-01 | 通用电气医疗集团股份有限公司 | 对比剂 |
WO2009047315A1 (en) | 2007-10-12 | 2009-04-16 | Ge Healthcare As | Contrast agents |
CN101891696A (zh) * | 2009-05-22 | 2010-11-24 | 史命锋 | 一种多碘苯环化合物及其制备方法和应用 |
WO2016079330A1 (en) | 2014-11-21 | 2016-05-26 | Technical University Of Denmark | Gel formulations for local drug release |
AU2017266410B2 (en) | 2016-05-20 | 2022-07-14 | Nanovi Radiotherapy Aps | Palpable marker composition |
EP3982922A1 (en) | 2019-06-12 | 2022-04-20 | Technical University of Denmark | Dissacharide formulations for controlled drug release |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI63064C (fi) * | 1980-04-09 | 1983-04-11 | Ksv Chemicals Oy | Foerfarande foer fluorometrisk bestaemning av aktiviteten av fettspjaelkande enzymer och medel foer att genomfoera foerfarandet |
US4873075A (en) | 1985-09-10 | 1989-10-10 | The University Of Michigan | Polyiodinated triglyceride analogs as radiologic agents |
US5851510A (en) | 1994-05-16 | 1998-12-22 | The Board Of Regents Of The University Of Michigan | Hepatocyte-selective oil-in-water emulsion |
-
2003
- 2003-03-27 WO PCT/JP2003/003814 patent/WO2003080554A2/en active Application Filing
- 2003-03-27 JP JP2003578313A patent/JP4464687B2/ja not_active Expired - Fee Related
- 2003-03-27 DE DE60324401T patent/DE60324401D1/de not_active Expired - Lifetime
- 2003-03-27 AT AT03715494T patent/ATE412641T1/de not_active IP Right Cessation
- 2003-03-27 US US10/507,486 patent/US7371877B2/en not_active Expired - Fee Related
- 2003-03-27 AU AU2003219554A patent/AU2003219554A1/en not_active Abandoned
- 2003-03-27 EP EP03715494A patent/EP1492776B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP4464687B2 (ja) | 2010-05-19 |
US20060062726A1 (en) | 2006-03-23 |
AU2003219554A8 (en) | 2003-10-08 |
US7371877B2 (en) | 2008-05-13 |
WO2003080554A3 (en) | 2004-04-15 |
EP1492776B1 (en) | 2008-10-29 |
EP1492776A2 (en) | 2005-01-05 |
ATE412641T1 (de) | 2008-11-15 |
AU2003219554A1 (en) | 2003-10-08 |
DE60324401D1 (de) | 2008-12-11 |
WO2003080554A2 (en) | 2003-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5064761B2 (ja) | ジエチレントリアミン型金属キレート構造を有する高級脂肪酸トリエステル及びアミド誘導体 | |
JP4464687B2 (ja) | グリセロールエステル誘導体 | |
JP4324343B2 (ja) | トリヨードフェニル基及びステロイド残基を有する化合物 | |
JP2006282604A (ja) | 金属キレート構造を有するグリセリンエステル誘導体 | |
JP4198592B2 (ja) | 二個のヨードフェニル基を有する1,3−グリセリド化合物 | |
JP2008297268A (ja) | ジエチレントリアミン型金属キレート構造を有する高級脂肪酸トリエステル化合物 | |
JP4833626B2 (ja) | ジエチレントリアミン型金属キレート構造を有する高級脂肪酸エステル及びアミド誘導体 | |
JP4344263B2 (ja) | 2個のヨードアリール基を有するジエステル化合物 | |
JP2004137203A (ja) | ヨードフェニル基を有する1,2−および1,3−グリセリド化合物 | |
EP1795208A1 (en) | Glycerophosphoric acid ester derivative having polyfunctional metal chelate structure | |
JP2005112783A (ja) | ヨードアリール基を有するリンゴ酸ステロイド誘導体 | |
JP4279505B2 (ja) | ヨードベンゼン化合物 | |
JP2004250343A (ja) | ヨードアリール基を有するアミノ酸誘導体 | |
JP2006069894A (ja) | トリヨードアリール基を有するカルボン酸エステル | |
JP2004231623A (ja) | ヨードアリール基を有するスレイトール誘導体 | |
JP4931527B2 (ja) | フッ素化ホスファチジルセリン化合物 | |
JP2004231622A (ja) | ヨードアリール基を有するペントース誘導体 | |
JP2004231624A (ja) | 1,2−グリセロールエステル誘導体 | |
JP2004292363A (ja) | ヨードアリール基を有するリン酸エステル誘導体 | |
JP2006069895A (ja) | トリヨードアリール基を有するアルキルアルコールのエステル化合物 | |
JP5090700B2 (ja) | ビス(トリフルオロメチル)フェニル基を有するグリセリド化合物 | |
JP2007182439A (ja) | 多官能性金属キレート構造を有するグリセロリン酸エステル | |
JP2004292362A (ja) | ヨードアリール基を有する炭酸エステル誘導体 | |
JP5053600B2 (ja) | 末端にフッ素を有するアルキル脂肪酸のステロイドエステル化合物 | |
JP2005068053A (ja) | ステロイド残基とヨードアリール基とを含むリン酸ジエステル化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060217 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20061214 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090901 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091007 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100216 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100219 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130226 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140226 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |